Search 

TheraCryf is a clinical stage drug development company focussed on the development of sulforaphane-based compounds, a new class of pharmaceuticals which are synthesised in a proprietary, well-tolerated, stable formulation. 

There is a comprehensive intellectual property package over this technology, covering novel compositions and manufacturing methods. 

TheraCryf exploits sulforaphane’s activity in three distinct disease-relevant cellular pathways; inhibition of pSTAT3, of importance in controlling cancer metastases, up-regulation of Nrf2, a therapeutic target associated with a broad range of diseases which are characterised by excessive oxidative stress, and inflammation and inhibition of SHP2, a target that has relevance in a number of solid tumours and haematological cancers.

Theramex is a global speciality pharmaceutical company solely committed to supporting the health needs of women through every stage of life. 

Theramex have helped millions of women around the world live better lives. They continue to work on patient-focused, effective solutions that support women of all ages.

They work closely with our partners, healthcare professionals, and patients to provide women with the right solution, at the time they most need it.

The imminent expiration of patents for major pharmaceutical drugs, known as the "patent cliff," not only opens the market for lower-priced generics but also presents a prime opportunity for biotech companies to secure valuable partnerships with pharma as they seek to revitalise their portfolios.